James Vardiman, M.D.

Hematopathology and Laboratory Hematology, Including Leukemia and Hairy Cell Leukemia

Research Summary

Selected Papers

Anastasi J, Feng J, Dickstein JI, Le Beau MM, Rubin C, Larson R, Rowley JD, Vardiman JW. (1996). Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemia: CML presenting in lymphoid blast crisis. Leukemia 10:795-802, 1996.

Koeppen H, Newell K, Baunoch DA, Vardiman JW. (1998). Morphologic bone marrow changes in patients with post-transplantation lymphoproliferative disorders. Am J Surg Pathol 22:208-214.

Koeppen H, Vardiman JW. (1998). New entities, issues and controversies in the classification of malignant lymphoma. Semin Oncology 25:421-434.

Jaffe ES, Diebold J, Harris NL, Muller-Hermelink HK, Flandrin G, Vardiman JW. (1999). Related Articles Burkitt's lymphoma: a single disease with multiple variants. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Blood. 93(3):1124.

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman JW, Lister TA, Bloomfield CD. (2000). World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia. Modern Pathology 13:193-207.

Anastasi J, Vardiman JW. (2000). Chronic myelogenous leukemia and the myeloproliferative disorders. In Neoplastic Hematopathology, D. Knowles Editor, Williams and Wilkens.

Vardiman JW. (2004). Myelodysplastic/myeloproliferative diseases. Cancer Treat Res. 121:13-43.

Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA, Vukosavljevic T, Perrotti D, Vardiman JW, Carroll AJ, Kolitz JE, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. (2006). Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 24(24):3904-11.

Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA Jr, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H; IWG for Myelofibrosis Research and Treatment (IWG-MRT). (2006). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 108(5):1497-503. Epub 2006 May 4.

Radmacher MD, Marcucci G, Ruppert AS, Mrozek K, Whitman SP, Vardiman JW, Paschka P, Vukosavljevic T, Baldus CD, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B. (2006). Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood. 108(5):1677-83. Epub 2006 May 2.

Cancer and Leukemia Group B 8461; Farag SS, Archer KJ, Mrozek K, Ruppert AS, Carroll AJ, Vardiman JW, Pettenati MJ, Baer MR, Qumsiyeh MB, Koduru PR, Ning Y, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. (2006). Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 108(1):63-73. Epub 2006 Mar 7.